Marie-Isabel Murray1,2,2, Mireira Jofre- Bonet3, Huseyin Naci2, Andreas M Zeiher1. 1. Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main, Germany. 2. Department of Health Policy, London School of Economics and Political Science, London, UK. 3. Department of Economics, University of London, London, UK.
Abstract
INTRODUCTION: The objective of this study was to evaluate the cost-effectiveness of the treatment with cryoballoon (CB) compared to the standard treatment with traditional irrigated radiofrequency (RF) ablation for pulmonary vein isolation in patients with paroxysmal atrial fibrillation (pAF) refractory to antiarrhythmic drug therapy. METHODS: A decision tree model was developed to graphically depict the probabilities, utilities and costs of CB compared to RF therapy. Data from a conducted systematic literature review and meta-analysis of only RCTs were used to evaluate clinical outcomes of CB and RF treatments, including success rates after one year, complications and recurrence of atrial fibrillation. RESULTS: The cost-utility analysis estimated that, CB therapy had £1,747 higher cost, and 0.0114 more quality-adjusted life years (QALYs) compared to standard RF treatment over a one-year time horizon. The incremental cost per QALY of CB ablation compared to RF ablation was estimated to be £152,836/QALY. CONCLUSIONS: Based on current evidence, CB ablation for pulmonary vein isolation in patients with pAF is costeffective compared to RF if decision makers are willing to pay £152,836 or higher for a QALY.
INTRODUCTION: The objective of this study was to evaluate the cost-effectiveness of the treatment with cryoballoon (CB) compared to the standard treatment with traditional irrigated radiofrequency (RF) ablation for pulmonary vein isolation in patients with paroxysmal atrial fibrillation (pAF) refractory to antiarrhythmic drug therapy. METHODS: A decision tree model was developed to graphically depict the probabilities, utilities and costs of CB compared to RF therapy. Data from a conducted systematic literature review and meta-analysis of only RCTs were used to evaluate clinical outcomes of CB and RF treatments, including success rates after one year, complications and recurrence of atrial fibrillation. RESULTS: The cost-utility analysis estimated that, CB therapy had £1,747 higher cost, and 0.0114 more quality-adjusted life years (QALYs) compared to standard RF treatment over a one-year time horizon. The incremental cost per QALY of CB ablation compared to RF ablation was estimated to be £152,836/QALY. CONCLUSIONS: Based on current evidence, CB ablation for pulmonary vein isolation in patients with pAF is costeffective compared to RF if decision makers are willing to pay £152,836 or higher for a QALY.
Authors: Hugh Calkins; Josep Brugada; Douglas L Packer; Riccardo Cappato; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; David E Haines; Michel Haissaguerre; Yoshito Iesaka; Warren Jackman; Pierre Jais; Hans Kottkamp; Karl Heinz Kuck; Bruce D Lindsay; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Andrea Natale; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Jeremy N Ruskin; Richard J Shemin Journal: Heart Rhythm Date: 2007-04-30 Impact factor: 6.343
Authors: David G Sherman; Soo G Kim; Bradley S Boop; Scott D Corley; John P Dimarco; Robert G Hart; L Julian Haywood; Keith Hoyte; Elizabeth S Kaufman; Michael H Kim; Elaine Nasco; Albert L Waldo Journal: Arch Intern Med Date: 2005-05-23
Authors: C McKenna; S Palmer; M Rodgers; D Chambers; N Hawkins; S Golder; S Van Hout; C Pepper; D Todd; N Woolacott Journal: Heart Date: 2008-12-18 Impact factor: 5.994
Authors: Matthew R Reynolds; Peter Zimetbaum; Mark E Josephson; Ethan Ellis; Tatyana Danilov; David J Cohen Journal: Circ Arrhythm Electrophysiol Date: 2009-04-17
Authors: David J Wilber; Carlo Pappone; Petr Neuzil; Angelo De Paola; Frank Marchlinski; Andrea Natale; Laurent Macle; Emile G Daoud; Hugh Calkins; Burr Hall; Vivek Reddy; Giuseppe Augello; Matthew R Reynolds; Chandan Vinekar; Christine Y Liu; Scott M Berry; Donald A Berry Journal: JAMA Date: 2010-01-27 Impact factor: 56.272